GLP-1 Microdosing: Does It Work? Cost, Providers & What the Science Says (2026)
GLP-1 microdosing — taking 0.05-0.125mg/week instead of standard 0.25-2.4mg — is trending. Here's what clinicians actually say, who offers it, and what it costs.
Microdosing GLP-1 medications — taking a fraction of the standard prescribed dose — is one of the most-asked questions we get from readers. Some patients want fewer side effects. Others want to stretch their supply. A growing minority believe small doses confer most of the metabolic benefit at a lower cost. Here is what the current evidence and prescribing reality actually look like.
Key takeaways
- Microdosing typically refers to weekly doses of 0.05–0.125 mg semaglutide, well below the standard 0.25–2.4 mg titration
- There is little randomized evidence at sub-therapeutic doses; most reports are anecdotal
- Compounded providers are the only route for true microdosing — brand-name pens deliver fixed standard doses
- Plan on $80–$150/month for compounded microdoses through a licensed telehealth program
What microdosing actually is
The pharmaceutical trials for semaglutide and tirzepatide were designed at specific therapeutic doses. The published weight-loss numbers — averaging 14.9% on semaglutide at 68 weeks and 15–22% on tirzepatide depending on dose — assume patients reach those targets. Microdosing intentionally stops well below them, often at the entry-titration level or lower.
Patients who choose microdosing usually report the same goals: fewer GI side effects, the ability to keep eating socially, slower but more sustainable weight loss, and lower monthly cost.
What the science says (and doesn't)
There is no peer-reviewed randomized trial directly comparing microdoses to standard doses for weight outcomes. What exists is small-sample real-world data and clinician case reports. Some endocrinologists argue that a meaningful share of GLP-1 benefit — appetite reduction, slower gastric emptying — appears at lower doses than the trials targeted, but the evidence is far from settled.
Until a registered trial is published, treat any specific microdose claim as informed clinical opinion, not proven outcome.
Where to get a microdose plan
Brand-name semaglutide and tirzepatide pens cannot be split safely or accurately — the manufacturer's dosing increments are fixed. To microdose responsibly you need a compounded vial that allows custom-volume injections under provider supervision.
Several telehealth providers in our review will work with patients on lower-than-typical doses. Eden Health, ShedRx, and a handful of compounding-focused programs are most flexible. See our full provider comparison for current pricing.